Apex Biotechnology Corp. (TPE:1733)

Apex Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	737.66	567.09	532.69	382.05	331.71	555.33
Trading Asset Securities	77.19	77.28	66.1	61.87	65.83	69.72
Cash & Short-Term Investments	814.85	644.37	598.78	443.91	397.53	625.05
Cash Growth	20.77%	7.61%	34.89%	11.67%	-36.40%	-24.05%
Accounts Receivable	399.13	437.8	346.64	288.39	486.77	474.41
Other Receivables	8.27	9.81	8.08	5.72	10.12	13.97
Receivables	407.4	447.61	354.72	294.11	496.89	488.38
Inventory	592.65	561.83	662.49	747.71	739.25	628.59
Prepaid Expenses	15.42	18.82	24.78	18.51	19	11.06
Other Current Assets	1.33	0.98	2.29	2.4	1.81	6.78
Total Current Assets	1,832	1,674	1,643	1,507	1,654	1,760
Property, Plant & Equipment	634.83	652.64	695.81	720.59	766.08	794.12
Other Intangible Assets	33.3	35.71	39.6	44.22	69.14	106.48
Long-Term Deferred Tax Assets	4.24	12.8	9.24	4.24	3.62	0.43
Other Long-Term Assets	46.64	41.06	32.23	21.32	21.38	9.58
Total Assets	2,551	2,416	2,420	2,297	2,515	2,670

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	229.96	231.7	239.03	156.22	289.69	343.89
Accrued Expenses	172.97	154.93	142.25	133.43	150.55	148.07
Short-Term Debt	-	-	-	30	50	150
Current Portion of Leases	5.76	7.69	9.03	7.2	8.01	6.88
Current Income Taxes Payable	30.82	25.88	24.52	46.24	36.92	40.12
Current Unearned Revenue	14.44	7.23	58.28	6.6	29.04	93.06
Other Current Liabilities	134.96	4.62	4.68	3.67	6.35	3.87
Total Current Liabilities	588.91	432.05	477.78	383.35	570.55	785.89
Long-Term Leases	100.69	101.98	113.93	116.2	122.67	127.66
Long-Term Deferred Tax Liabilities	0.85	10.82	3.54	0.04	3.1	2.88
Other Long-Term Liabilities	0.49	0.47	0.47	0.48	0.49	0.48
Total Liabilities	690.93	545.32	595.7	500.07	696.81	916.91

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	999.5	999.5	999.5	999.5	999.5	999.5
Additional Paid-In Capital	68.37	-	-	68.37	68.37	68.37
Retained Earnings	779.35	791.23	744.06	718.87	739.95	682.34
Comprehensive Income & Other	11.54	78.98	80.04	9.69	9.51	2.52
Total Common Equity	1,859	1,870	1,824	1,796	1,817	1,753
Minority Interest	0.96	0.77	0.63	0.5	0.57	0.82
Shareholders' Equity	1,860	1,870	1,824	1,797	1,818	1,754
Total Liabilities & Equity	2,551	2,416	2,420	2,297	2,515	2,670

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	106.45	109.67	122.96	153.4	180.68	284.55
Net Cash (Debt)	708.41	534.69	475.83	290.52	216.85	340.5
Net Cash Growth	26.27%	12.37%	63.79%	33.97%	-36.31%	10.11%
Net Cash Per Share	7.04	5.32	4.74	2.90	2.15	3.22
Filing Date Shares Outstanding	99.95	99.95	99.95	99.95	99.95	99.95
Total Common Shares Outstanding	99.95	99.95	99.95	99.95	99.95	99.95
Working Capital	1,243	1,242	1,165	1,123	1,084	973.97
Book Value Per Share	18.60	18.71	18.25	17.97	18.18	17.54
Tangible Book Value	1,825	1,834	1,784	1,752	1,748	1,646
Tangible Book Value Per Share	18.26	18.35	17.85	17.53	17.49	16.47
Land	261.68	261.68	261.68	261.68	261.68	261.68
Buildings	605.29	605.02	605.02	604.13	604.13	601.96
Machinery	819.73	816.08	806.49	789.71	777.35	754.25

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error